Építés alatt – nem éles oldal
Belépés

NCT07646561Befejeződött

Transcranial Doppler in Preeclampsia and Its Complications.

the Diagnostic and Prognostic Value of Transcranial Doppler in Preeclampsia and Its Complications.

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 12.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. It is defined by new-onset hypertension after 20 weeks of gestation, often associated with proteinuria and/or systemic complications such as thrombocytopenia, renal impairment, hepatic dysfunction, neurological symptoms, pulmonary edema, or intrauterine growth restriction. Neurological involvement is particularly severe, as it may progress to eclampsia, intracerebral hemorrhage, or ischemic stroke. Detecting early cerebral hemodynamic changes is therefore essential. Transcranial Doppler (TCD) is a non-invasive ultrasound technique that measures cerebral blood flow velocities, particularly in the middle cerebral artery (MCA). It provides systolic, diastolic, and mean velocity values, and calculates indices such as pulsatility index (PI), resistance index (RI), cerebral perfusion pressure (CPP), resistance area product (RAP), cerebral flow index (CFI), and Lindegaard index (LI). These parameters can detect impaired cerebral autoregulation, hyperemia, vasospasm, or cerebral hypoperfusion. Although several studies suggest that preeclampsia is associated with altered cerebral hemodynamics, the diagnostic and prognostic role of TCD remains insufficiently defined. The objective of this prospective, observational, case-control study is to evaluate the diagnostic and prognostic value of TCD in preeclampsia and its complications. The study will be conducted at the Maternity and Neonatology Center of Tunis (Departments of Anesthesia, Intensive Care, and Gynecology-Obstetrics A-D) over six months, from January to June 2025. Participants will be pregnant women in their third trimester, divided into two groups: * Group A: preeclamptic women, defined by hypertension and proteinuria after 20 weeks of gestation, or hypertension/proteinuria with at least one severity criterion (hematologic, hepatic, renal, pulmonary, neurological, or fetal). * Group B: normotensive, non-preeclamptic controls. Exclusion criteria include chronic hypertension, chronic kidney disease, epilepsy, hematologic disease, cardiac or liver disease, COPD, severe anemia, technical difficulties preventing TCD, loss to follow-up, or diagnostic uncertainty. Women with isolated gestational hypertension will also be excluded. TCD will be performed via the temporal window using a 2 MHz pulsed Doppler probe, mainly focusing on the MCA. In Group A, measurements will be obtained before and after antihypertensive therapy, before and after magnesium sulfate administration when indicated, and before and after any complications. In Group B, a single TCD will be performed during the third trimester. The study will compare cerebral blood flow velocities and indices between groups and monitor their evolution over time. Data interpretation will allow classification of findings into patterns such as systemic hypoperfusion, cerebral hypoperfusion with elevated intracranial pressure, hyperemia, or vasospasm. The expected outcome is to establish whether TCD can serve as a reliable diagnostic and prognostic tool in preeclampsia. The results will contribute to a better understanding of cerebrovascular physiology in this condition and may help identify women at higher risk of neurological or systemic complications. Ultimately, this work aims to highlight TCD as a simple, reproducible, and non-invasive tool for clinical management and risk stratification in preeclampsia.

Állapot (regiszter)
Befejeződött
Vizsgálattípus
Megfigyeléses
Résztvevők száma
100 (tényleges)
Első benyújtás
2025. aug. 31.
Kezdés
2025. jan. 1.
Elsődleges befejezés
2025. jún. 30.
Fő szponzor
University Tunis El Manar
NCT-szám
NCT07646561

Mit vállalsz

  • Vizsgálat típusa: Megfigyeléses
  • Bevont résztvevők: 100
  • 2025. jan. 1. és az elsődleges befejezés (2025. jún. 30.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Más betegség

  • History of significant neurological or cardiovascular disease
  • Active infection or major medical complication

Laborértékek

  • Allergy or contraindication to antihypertensive therapy or magnesium sulfate

Egyéb

  • Multiple pregnancy (twins, triplets, etc.)
  • Refusal to provide informed consent

Kiket keres a vizsgálat

  • Consenting pregnant women in their third trimester (28 weeks of gestation or more)
  • Group A: Patients with preeclampsia, defined as:
  • Systolic Blood Pressure (SBP) equal to or greater than 140 mmHg and/or Diastolic Blood Pressure (DBP) equal to or greater than 90 mmHg appearing after 20 weeks of gestation with 24-hour proteinuria equal to or greater than 300 mg/24h, or
  • SBP equal to or greater than 140 mmHg and/or DBP equal to or greater than 90 mmHg or 24-hour proteinuria equal to or greater than 300 mg/24h with at least one of the following
  • Thrombocytopenia, platelets below 100,000 per cubic millimeter
  • Liver cytolysis, AST or ALT more than 2 times normal values
  • Hemolytic anemia (schistocytes present, LDH above 600)
  • Serum creatinine equal to or greater than 90 micromoles per liter and oliguria equal to or less than 500 milliliters per 24 hours, excluding functional or obstructive causes
  • Acute pulmonary edema
  • Subcapsular liver hematoma
  • Neurological or sensory signs (headache, blurred vision, tinnitus, hyperreflexia, diffuse polykinetic reflexes)
  • Eclampsia
  • Severe intrauterine growth restriction
  • Group B: Healthy, normotensive pregnant women
  • SBP less than 140 mmHg and DBP less than 90 mmHg
  • No clinical or biological signs of severe preeclampsia
  • Negative 24-hour proteinuria test, less than 300 mg/24h, if performed

Életkor a regiszterben: 18 év – 45 év · Nem: csak nők · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Tunis maternity and neonatology center, ministery of public health, Tunis ,1007TunisTunéziaIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.